Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Verastem, Inc.VSTM · Entity 5242 | Chief Strategy Officer | January 03, 2019 | January 07, 2019 |
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Chief Business Officer | May 01, 2025 | May 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Verastem, Inc.
Report date January 03, 2019 · Filed January 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2029-01-03 | Direct | 40,000 |
Reported balance
After 2019-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-03 · Grant · Acquired 40,000 · Balance 40,000 F1: The option vests as to 25% of the shares on the first anniversary of January 1, 2019 (the "Commencement Date") and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Commencement Date until the fourth anniversary of the Commencement Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2029-01-03 | Direct | 40,000 |
Reported balance
After 2019-01-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-03 · Grant · Acquired 40,000 · Balance 40,000 F2: The option vests as to: (a) 40% of the shares upon the date on which the closing price per share of the common stock is at least $10.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, (b) 40% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $15.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, and (c) 20% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $20.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the shares on the first anniversary of January 1, 2019 (the "Commencement Date") and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Commencement Date until the fourth anniversary of the Commencement Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date.
F2: The option vests as to: (a) 40% of the shares upon the date on which the closing price per share of the common stock is at least $10.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, (b) 40% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $15.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, and (c) 20% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $20.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date.
Werewolf Therapeutics, Inc.
Report date May 01, 2025 · Filed May 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2035-04-30 | Direct | 201,720 |
Reported balance
After 2025-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-01 · Grant · Acquired 201,720 · Balance 201,720 F1: The option was granted as an inducement material to Mr. Bloom's entering into employment with Werewolf Therapeutics, Inc. (the "Company") in accordance with Nasdaq Listing Rule 5635(c)(4). The option has a ten-year term and vests as to 25% on April 16, 2026, the first anniversary of the effective date of Mr. Bloom's employment, and the remaining 75% vests in 36 equal monthly installments thereafter, subject to continued service by Mr. Bloom to the Company or any of its subsidiaries through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted as an inducement material to Mr. Bloom's entering into employment with Werewolf Therapeutics, Inc. (the "Company") in accordance with Nasdaq Listing Rule 5635(c)(4). The option has a ten-year term and vests as to 25% on April 16, 2026, the first anniversary of the effective date of Mr. Bloom's employment, and the remaining 75% vests in 36 equal monthly installments thereafter, subject to continued service by Mr. Bloom to the Company or any of its subsidiaries through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2025 Filed May 2, 2025 17:38 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 201,720 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0000950170-25-062970 · ownership.xml · derivative · entry 1 Bloom Steven H. · CIK 0001722642 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,720 Underlying: Common Stock · 201,720 shares Expires 2035-04-30 F1 · derivative.exercise_date: The option was granted as an inducement material to Mr. Bloom's entering into employment with Werewolf Therapeutics, Inc. (the "Company") in accordance with Nasdaq Listing Rule 5635(c)(4). The option has a ten-year term and vests as to 25% on April 16, 2026, the first anniversary of the effective date of Mr. Bloom's employment, and the remaining 75% vests in 36 equal monthly installments thereafter, subject to continued service by Mr. Bloom to the Company or any of its subsidiaries through each applicable vesting date. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:55 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000904454-19-000032 · edgar.xml · derivative · entry 2 Bloom Steven H. · CIK 0001722642 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-01-03 F2 · derivative.exercise_date: The option vests as to: (a) 40% of the shares upon the date on which the closing price per share of the common stock is at least $10.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, (b) 40% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $15.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, and (c) 20% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $20.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:55 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000904454-19-000032 · edgar.xml · derivative · entry 1 Bloom Steven H. · CIK 0001722642 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-01-03 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of January 1, 2019 (the "Commencement Date") and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Commencement Date until the fourth anniversary of the Commencement Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| September 24, 2018 Filed Oct 2, 2018 22:32 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0000904454-18-000621 · edgar.xml · derivative · entry 1 Bloom Steven H. · CIK 0001722642 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2028-01-05 F1 · shares: On January 5, 2018, the Reporting Person was granted an option to purchase 70,000 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by June 30, 2018, by March 31, 2019, and within the first twenty-four (24) months after the achievement of certain net sales targets. 20% of the performance criteria was met on April 6, 2018, resulting in vesting of the option as to 14,000 shares. 40% of the performance criteria was met on September 24, 2018, resulting in vesting of the option as to 28,000 shares. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 22:58 UTC | Verastem, Inc. VSTM · Entity 5242 | PurchaseCommon Stock | 3,000 | $5.98 | $17,940.00 |
DisclosureSEC source: 0001104659-18-039656 · a4.xml · nonDerivative · entry 1 Bloom Steven H. · CIK 0001722642 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| April 06, 2018 Filed Jun 4, 2018 21:56 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001104659-18-038055 · a4.xml · derivative · entry 1 Bloom Steven H. · CIK 0001722642 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-01-05 F1 · balance_after: On January 5, 2018, the Reporting Person was granted an option to purchase 70,000 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by June 30, 2018, by March 31, 2019, and within the first twenty-four (24) months after the achievement of certain net sales targets. 20% of the performance criteria was met on April 6, 2018, resulting in vesting of the option as to 14,000 shares. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 22:46 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001104659-18-001512 · a4.xml · derivative · entry 1 Bloom Steven H. · CIK 0001722642 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-01-05 F1 · derivative.exercise_date: 25% of this option will vest on January 1, 2019 and 6.25% of this option will vest at the end of each successive three-month period thereafter until January 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.